Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

AYAndrew L. Young

Discussion

Loading...

Member takes

Overview

Case report reveals daratumumab's potential to improve platelet counts in multi-refractory immune thrombocytopenia, suggesting new therapeutic avenues.

Key Points

  • To explore the efficacy of daratumumab for treating multi-refractory immune thrombocytopenia (ITP).
  • Case report of a 62-year-old man with multi-refractory ITP receiving daratumumab.
  • Treatment history included steroids, rituximab, and other therapies without success.
  • Daratumumab was administered off-label with fostamatinib and danazol after multiple failed therapies.
  • Patient achieved a rapid platelet count normalization within five days of daratumumab treatment.
  • Remains in stable remission with platelet counts >300,000/μL for 14 months post-diagnosis.
  • Patient tolerated daratumumab well alongside other medications without significant adverse effects.

Cite This Study

Andrew L. Young (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbd0https://doi.org/10.1182/blood-2025-6602
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term remissions in refractory ITP patients by daratumumab2025 · 1 citations
  2. 2Efficacy of <scp>CD38</scp> ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series2026
  3. 3Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab2026
  4. 4Safety and Efficacy of Daratumumab in Immune Thrombocytopenia2025 · 16 citations
  5. 5Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.2026